Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance

Blood

Volumn 96, Issue 3, 2000, Pages 1070-1079

  Mahon, F X ^a   Deininger, M W N ^a   Schultheis, B ^a   Chabrol, J ^a   Reiffers, J ^a   Goldman, J M ^a   Melo, J V ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CASPASE 3; GLYCOPROTEIN P; IMATINIB; INTERLEUKIN 3; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CELL SELECTION; CELL STRAIN K 562; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LYMPHOCYTE CLONE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0034254368     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.3.1070.015k17_1070_1079     Document Type: Article

References (38)

1. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype
2. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining [letter]
3. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
4. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products
5. Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: Abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1- positive leukemia cell growth
6. Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate
7. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
8. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
9. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL positive cells
10. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+leukemic cells and induces apoptosis
11. Phase I trial of a specific ABL tyrosine kinase inhibitor, CGP57148 in interferon refractory chronic myelogenous leukemia patients [abstract]
12. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein
13. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction
14. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR-ABL tyrosine kinase CGP 57148
15. A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells
16. Single-step method of RNA isolation by acid guanidinium thiocyanate- phenol-chloroform extraction
17. Characterization of BCR promoter in Philadelphia chromosome-positive and negative cell lines
18. Unique organization of the human BCR gene promoter
19. Extensive amplification of bcr/abl fusion genes clustered on the three marker chromosome in human leukemic cell line K-562
20. Reversal of multi-drug resistance in hematological malignancies
21. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia
22. Nucleotide sequence analysis of human abl and bcr-abl cDNAs
23. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
24. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor
25. Clinical significance of P-glycoprotein in multidrug resistance malignancies
26. Bcr-Abl translocation can occur during the induction of multidrug resistance and confers apoptosis resistance on myeloid leukemic cell lines
27. Clinical significance of multidrug resistance P-glyco-protein expression on acute nonlymphoblastic leukemia cells at diagnosis
28. Increased mdr gene expression and decreased drug accumulation in multidrug-resistant human melanoma cells
29. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
30. Bcr: A negative regulator of the Bcr-Abl oncoprotein
31. Biochemical and genetic control of apoptosis: Relevance to normal hematopoiesis and hematological malignancies
32. Correlation between leukemic cell retention of 1-B- arabinofurasylcytosine 5'-triphosphate and response to therapy
33. Differences in uptake of adriamycin and daunorubicin by normal BM cells and acute leukemia cells determined by flow cytometry
34. Expression of multidrug resistance-associated protein (MRP) in acute leukaemia
35. Chromosome abnormalities in malignant hematologic diseases
36. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression
37. Correlation between the proportion of Philadelphia chromosome-positive metaphase cells and levels of BCR-ABL mRNA in chronic myeloid leukaemia
38. Expression of multidrug transporter, P-glycoprotein, in chronic myelogenous leukaemia cells in blast crisis